Download PDF
Semin Thromb Hemost 2025; 51(02): 138-144
DOI: 10.1055/s-0044-1789595
Review Article

Clinical, Laboratory Aspects and Management of Factor X Deficiency

Marzia Menegatti
1   Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
,
Flora Peyvandi
1   Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
2   Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Coagulation factor X (FX), originally named Stuart–Prower factor, plays a pivotal role in the coagulation cascade, activating thrombin to promote platelet plug formation and prevent excess blood loss. Genetic variants in F10 may lead to FX deficiency and to impaired coagulation. FX variants are phenotypically classified as being type I, with the concomitant reduction of FX coagulant activity and FX antigen levels or type II, corresponding to a reduction in activity with normal antigen plasma levels. Patients affected with FX deficiency tend to be one of the most seriously affected among those with rare bleeding disorders. They show a variable bleeding tendency strongly associated with FX coagulant activity levels in plasma and may present, in the severe form of the deficiency, life-threatening symptoms such as gastrointestinal and umbilical stump bleeding and intracranial hemorrhages or central nervous system bleeding. Treatment of FX deficiency was originally based on the replacement of the missing factor using fresh frozen plasma, cryoprecipitate and prothrombin complex concentrates; however, a plasma-derived concentrate, shown to be safe and effective in clinical trials, is now available. In addition, novel nonreplacement therapy such as small interference RNA, gene therapy, drug repurposing, and gene editing may also represent novel therapeutic approaches for FX deficiency, but further, much focused studies are needed before considering this emerging therapy in such patients.

Keywords

bleeding disorders - factor X - factor X deficiency - gene mutations - replacement therapy


Publication History

Article published online:
29 August 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Lippi G, Franchini M, Montagnana M, Favaloro EJ. Inherited disorders of blood coagulation. Ann Med 2012; 44 (05) 405-418
    CrossrefPubMedSearch in Google Scholar
  • 2 Camire RM. Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics. J Thromb Thrombolysis 2021; 52 (02) 383-390
    CrossrefPubMedSearch in Google Scholar
  • 3 Troisi R, Balasco N, Autiero I, Sica F, Vitagliano L. New insight into the traditional model of the coagulation cascade and its regulation: illustrated review of a three-dimensional view. Res Pract Thromb Haemost 2023; 7 (06) 102160
    CrossrefPubMedSearch in Google Scholar
  • 4 Mumford AD, Ackroyd S, Alikhan R. et al; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (03) 304-326
    CrossrefPubMedSearch in Google Scholar
  • 5 Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost 2009; 35 (04) 407-415
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Seidizadeh O, Cairo A, Baronciani L, Valenti L, Peyvandi F. Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases. NPJ Genom Med 2023; 8 (01) 31
    CrossrefPubMedSearch in Google Scholar
  • 7 Wright IS. The nomenclature of blood clotting factors. Can Med Assoc J 1962; 86 (08) 373-374
    PubMedSearch in Google Scholar
  • 8 Peyvandi F, Palla R, Menegatti M. et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (04) 615-621
    CrossrefPubMedSearch in Google Scholar
  • 9 Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A. Project on Consensus Definitions in Rare Bleeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012; 10 (09) 1938-1943
    CrossrefPubMedSearch in Google Scholar
  • 10 Girolami A, Cosi E, Santarossa C, Ferrari S, Girolami B, Lombardi AM. Factor X Friuli coagulation disorder: almost 50 years later. Clin Appl Thromb Hemost 2018; 24 (01) 33-40
    CrossrefPubMedSearch in Google Scholar
  • 11 Herrmann FH, Auerswald G, Ruiz-Saez A. et al; Greifswald Factor X Deficiency Study Group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006; 12 (05) 479-489
    CrossrefPubMedSearch in Google Scholar
  • 12 Peyvandi F, Mannucci PM, Lak M. et al. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol 1998; 102 (02) 626-628
    CrossrefPubMedSearch in Google Scholar
  • 13 Peyvandi F, Menegatti M, Santagostino E. et al. Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency. Br J Haematol 2002; 117 (03) 685-692
    CrossrefPubMedSearch in Google Scholar
  • 14 Diesch T, von der Weid NX, Schifferli A, Kühne T. Intracranial hemorrhage as the first manifestation of severe congenital factor X deficiency in a 20-month-old male: case report and review of the literature. Pediatr Blood Cancer 2016; 63 (07) 1300-1304
    CrossrefPubMedSearch in Google Scholar
  • 15 Krumb E, Mehta N, Hutchinson C. et al. Postmortem diagnosis of severe factor X deficiency in a fetus with intracranial hemorrhage resulting in intrauterine death. J Thromb Haemost 2023; 21 (12) 3501-3507
    CrossrefPubMedSearch in Google Scholar
  • 16 Grottke O, Moser O, Farrag A, Elbracht M, Orlikowsky T, Trepels-Kottek S. Plasma-derived factor X therapy for treatment of intracranial bleeding in a patient with factor X deficiency: a case report. Transfusion 2019; 59 (07) 2228-2233
    CrossrefPubMedSearch in Google Scholar
  • 17 Peyvandi F, Auerswald G, Austin SK. et al. Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. Blood Rev 2021; 50: 100833
    CrossrefPubMedSearch in Google Scholar
  • 18 Girolami A, Scarparo P, Scandellari R, Allemand E. Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation. Am J Hematol 2008; 83 (08) 668-671
    CrossrefPubMedSearch in Google Scholar
  • 19 Leytus SP, Chung DW, Kisiel W, Kurachi K, Davie EW. Characterization of a cDNA coding for human factor X. Proc Natl Acad Sci U S A 1984; 81 (12) 3699-3702
    CrossrefPubMedSearch in Google Scholar
  • 20 Leytus SP, Foster DC, Kurachi K, Davie EW. Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 1986; 25 (18) 5098-5102
    CrossrefPubMedSearch in Google Scholar
  • 21 Carnbring Bonde A, Rosenørn Hansen S, Johansson E, Rose Bjelke J, Lund J. Site-specific functional roles of the factor X activation peptide in the intrinsic tenase-mediated factor X activation. FEBS Lett 2022; 596 (12) 1567-1575
    CrossrefPubMedSearch in Google Scholar
  • 22 Reddy SV, Zhou ZQ, Rao KJ. et al. Molecular characterization of human factor X San Antonio. Blood 1989; 74 (05) 1486-1490
    CrossrefPubMedSearch in Google Scholar
  • 23 Bastida JM, Benito R, Lozano ML. et al. Molecular diagnosis of inherited coagulation and bleeding disorders. Semin Thromb Hemost 2019; 45 (07) 695-707
    Thieme ConnectPubMedSearch in Google Scholar
  • 24 Harris VA, Lin W, Perkins SJ. Analysis of 180 genetic variants in a new interactive FX variant database reveals novel insights into FX deficiency. TH Open 2021; 5 (04) e557-e569
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Cohen AJ, Kessler CM. Treatment of inherited coagulation disorders. Am J Med 1995; 99 (06) 675-682
    CrossrefPubMedSearch in Google Scholar
  • 26 Benhamou D. The use of fresh frozen plasma (FFP) in 2007 in France. Transfus Clin Biol 2007; 14 (06) 557-559
    CrossrefPubMedSearch in Google Scholar
  • 27 Nair PM, Rendo MJ, Reddoch-Cardenas KM, Burris JK, Meledeo MA, Cap AP. Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease. Semin Hematol 2020; 57 (02) 73-82
    CrossrefPubMedSearch in Google Scholar
  • 28 Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates–evaluation of safety and thrombogenicity. Crit Care 2011; 15 (01) 201
    CrossrefPubMedSearch in Google Scholar
  • 29 Behring Factor X P. https://www.refdata.ch/images/AIPS_ENG_PDF/factor_x_p_behring.pdf
    PubMed
  • 30 Karimi M, Vafafar A, Haghpanah S. et al. Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe factor X deficiency in Iran. Haemophilia 2012; 18 (02) 211-215
    CrossrefPubMedSearch in Google Scholar
  • 31 Coagadex. https://www.coagadex.com/download/Coagadex-USPI_14-Apr-2023.pdf
    PubMed
  • 32 Shapiro A. Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety. Expert Opin Drug Metab Toxicol 2017; 13 (01) 97-104
    CrossrefPubMedSearch in Google Scholar
  • 33 Escobar MA, Kavakli K. Plasma-derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency. Haemophilia 2024; 30 (01) 59-67
    CrossrefPubMedSearch in Google Scholar
  • 34 Auerswald G. Prophylaxis in rare coagulation disorders – factor X deficiency. Thromb Res 2006; 118 (Suppl. 01) S29-S31
    CrossrefPubMedSearch in Google Scholar
  • 35 Payne J, Batsuli G, Leavitt AD, Mathias M, McGuinn CE. A review of the pharmacokinetics, efficacy and safety of high-purity factor X for the prophylactic treatment of hereditary factor X deficiency. Haemophilia 2022; 28 (04) 523-531
    CrossrefPubMedSearch in Google Scholar
  • 36 Spiliopoulos D, Kadir RA. Congenital factor X deficiency in women: a systematic review of the literature. Haemophilia 2019; 25 (02) 195-204
    CrossrefPubMedSearch in Google Scholar
  • 37 Gualtierotti R, Pasca S, Ciavarella A. et al. Updates on novel non-replacement drugs for hemophilia. Pharmaceuticals (Basel) 2022; 15 (10) 1183
    CrossrefPubMedSearch in Google Scholar
  • 38 Qian K, Liu J, Huang S, Akin A. Thrombin generation response with the addition of bypassing agents in plasma of patients treated with fitusiran. Hemophilia 2018; 24 (Suppl5): MP-219
    PubMedSearch in Google Scholar
  • 39 Verhenne S, McCluskey G, Maynadié H. et al. Fitusiran reduces bleeding in factor X-deficient mice. Blood 2024; 144 (02) 227-236
    CrossrefPubMedSearch in Google Scholar
  • 40 Leong L, Byun T, Kim B. et al. Pre-clinical characterization of VGA039, an anti-protein s monoclonal antibody being developed as a universal hemostatic agent for various bleeding disorders. Blood 2022; 140 (Suppl. 01) 1666-1667
    CrossrefPubMedSearch in Google Scholar
  • 41 Rakhe S, Patel-Hett SR, Bowley S, Murphy JE, Pittman DD. The tissue factor pathway inhibitor antibody, PF-06741086, increases thrombin generation in rare bleeding disorder and von Willebrand factor deficient plasmas. Blood 2018; 132 (Suppl. 01) 2462
    CrossrefPubMedSearch in Google Scholar
  • 42 Arruda VR, Weber J, Samelson-Jones BJ. Gene therapy for inherited bleeding disorders. Semin Thromb Hemost 2021; 47 (02) 161-173
    Thieme ConnectPubMedSearch in Google Scholar
  • 43 Andresen M, Andersen E, Mowinckel M, Stavik B, Sandset P, Chollet M. Evaluation of pharmacological enhancers of mutated factor VII activity ex vivo. [abstract] Res Pract Thromb Haemost 2021; 5 (Suppl. 02) e12589
    PubMedSearch in Google Scholar
  • 44 De Pablo-Moreno JA, Miguel-Batuecas A, Rodríguez-Merchán EC, Liras A. Treatment of congenital coagulopathies, from biologic to biotechnological drugs: the relevance of gene editing (CRISPR/Cas). Thromb Res 2023; 231: 99-111
    CrossrefPubMedSearch in Google Scholar